IntroductionIn 2011, the FDA issued an alert recommending not to prescribe citalopram high
doses, due to QT prolongation risk. We explored the clinical background of QT interval …

Objective: To evaluate the association between selective serotonin reuptake inhibitors
(SSRIs) and corrected QT interval (QTc) prolongation via meta-analysis of prospective …

Introduction: Evidence increasingly points to the potential development of harmful cardiac
side effects concomitant with the use of a number of psychotropic drugs, primarily traditional …

According to a recent cross-sectional study, some antidepressants, including amitriptyline,
citalopram and escitalopram, are associated with QTc prolongation. However, the …

Background Some psychotropic medications have been associated with prolongation of the
QT interval and QT prolongation, especially in those with medical illness, and are linked to …

Background Prolongation of the corrected QT (QTc) interval is a key issue for patients who
receive psychotropic medications. Such patients may have baseline clinical risk factors for …

Objective: To report QT prolongation potential in selective serotonin reuptake inhibitors
(SSRIs) in order to advise clinicians on safe use of SSRIs other than citalopram in light of …

In 2011/2012, the US Food and Drug Administration issued a warning about the effect of
citalopram on the QT interval and decreased its dosing. Further studies addressing this …

Whether or not QTc interval should be routinely monitored in patients receiving
antipsychotics is a controversial issue, given logistic and fiscal dilemmas. There is a link …

Background QT interval prolongations were described with citalopram and escitalopram.
However, the effects of the other serotonin reuptake inhibitors (SRIs) remained discussed. In …